Download PDF
Semin Liver Dis 2003; 23: 023-028
DOI: 10.1055/s-2003-41631
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pharmacokinetics of Peginterferons

Stefan Zeuzem, Christoph Welsch, Eva Herrmann
  • Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg/Saar, Germany
Further Information

Publication History

Publication Date:
21 August 2003 (online)

    Permissions and Reprints

ABSTRACT

Two polyethylene glycol (PEG)-modified interferons are approved for the treatment of chronic hepatitis C. The pharmocokinetic properties of the branched 40 kDa pegylated interferon alfa-2a differ from the linear 12 kDa pegylated interferon alfa-2b. The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively. The volume of distribution for peginterferon alfa-2a is considerably restricted, while the volume of distribution for peginterferon alfa-2b is only approximately 30% lower than that for conventional interferon. Because of its large size, the 40 kD peginterferon alfa-2a has a more than 100-fold reduction in renal clearance compared with conventional interferon alfa. Clearance of peginterferon alfa-2b is about one-tenth that of unmodified interferon alfa. Although data are limited, both drugs appear to show differences in the initial viral decay pattern in patients with chronic hepatitis C. However, it remains unknown whether these differences in the initial viral decline predict differences in the primary clinical endpoint, sustained virological response.

KEYWORDS

Peginterferon alfa-2a - peginterferon alfa-2b - pharmacokinetics - viral kinetics

REFERENCES

  • 1 Harris J M, Martin N E, Modi M. Pegylation. A novel process for modifying pharmacokinetics.  Clin Pharmacokinet . 2001;  40 539-551
    CrossrefPubMedGoogle Scholar
  • 2 Delgado C, Francis G E, Fisher D. The uses and properties of PEG-linked proteins.  Critical Reviews in Therapeutic Drug Carrier Systems . 1992;  9 249-304
    PubMedGoogle Scholar
  • 3 Pestka S, Langer J A, Zoon K C, Samuel C E. Interferons and their actions.  Annu Rev Biochem . 1987;  56 727-777
    PubMedGoogle Scholar
  • 4 Wills R J. Clinical pharmacokinetics of interferons.  Clin Pharmacokinet . 1990;  19 390-399
    CrossrefPubMedGoogle Scholar
  • 5 Monkarsh S P, Ma Y, Aglione A. et al . Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.  Anal Biochem . 1997;  247 434-440
    CrossrefPubMedGoogle Scholar
  • 6 O'Brian C, Pockros P, Reddy R. et al . A double-blind, multicenter, randomized, parallel dose-comparison study of six regimens of 5 kD, linear peginterferon alfa-2a compared with Roferon-A in patients with chronic hepatitis C.  Antiviral Therapy . 1999;  4(Suppl) 27
    PubMedGoogle Scholar
  • 7 Grace M, Youngster S, Gitlin G. et al . Structural and biologic characterization of pegylated recombinant IFN-α2b.  J Interferon Cytokine Res . 2001;  21 1103-1115
    CrossrefPubMedGoogle Scholar
  • 8 Glue P, Rouzier-Panis R, Raffanel C. et al . A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.  Hepatology . 2000;  32 647-653
    CrossrefPubMedGoogle Scholar
  • 9 Glue P, Fang J, Rouzier-Panis R. et al . Pegylated interferon alfa-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data.  Clin Pharmacol Ther . 2000;  68 556-567
    PubMedGoogle Scholar
  • 10 Lindsay K L, Trepo C, Heintges T. et al . A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.  Hepatology . 2001;  34 395-403
    CrossrefPubMedGoogle Scholar
  • 11 Peginterferon alfa-2b product monograph. Kenilsworth, NJ: Schering-Plough 2001
    Google Scholar
  • 12 Bailon P, Palleroni A, Schaffer C A. et al . Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C.  Bioconjug Chem . 2001;  12 195-202
    CrossrefPubMedGoogle Scholar
  • 13 Algranati N E, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) (Abst).  Hepatology . 1999;  30(Suppl) 190A
    PubMedGoogle Scholar
  • 14 Modi M W, Fried M, Reindollar R W. et al . The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a in chronic hepatitis C after multiple dosing (Abst).  Hepatology . 2000;  32(Suppl) 394A
    CrossrefPubMedGoogle Scholar
  • 15 Peginterferon alfa-2a product monograph. Nutley, NJ: Hoffman-La Roche 2002
    Google Scholar
  • 16 Heathcote E J, Pockros P J, Fried M W. et al . The pharmacokinetics of pegylated-40K interferon alfa-2a (PEG-IFN) in chronic hepatitis C (CHC) patients with cirrhosis (Abst).  Gastroenterology . 1999;  116(Suppl) A735
    PubMedGoogle Scholar
  • 17 Modi M W, Fulton J S, Buckmann D K. et al . Clearance of pegylated (40kDa) interferon alfa-2a is primarily hepatic (Abst).  Hepatology . 2000;  32(Suppl) 371A
    PubMedGoogle Scholar
  • 18 Martin P, Mitra S, Farrington K. et al . Pegylated (40kDa) interferon alfa-2a is unaffected by renal impairment (Abst).  Hepatology . 2000;  32(Suppl) 370A
    PubMedGoogle Scholar
  • 19 Lamb M W, Marks I M, Wynohradnyk L. et al . 40 kDa peginterferon alfa-2a can be administered safely in patients with end-stage renal disease (Abst).  Hepatology . 2001;  34(Suppl) 326A
    PubMedGoogle Scholar
  • 20 Martin N E, Modi M W, Reddy K R. Characterization of pegylated (40kDa) interferon alfa-2a in the elderly (Abst).  Hepatology . 2000;  32(Suppl) 348A
    CrossrefPubMedGoogle Scholar
  • 21 Davis G L, Balan V, Sulkowski M S. et al . A phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of escalating doses of a novel recombinant human albumin-interferon α fusion protein (Albuferon) in subjects with chronic hepatitis C (Abst).  Hepatology . 2002;  36(Suppl) 285A
    PubMedGoogle Scholar
  • 22 Xu Z-X, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmaco-kinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects (Abst).  Hepatology . 1998;  28(Suppl) 702A
    PubMedGoogle Scholar
  • 23 Kamal S M, Fehr J, Roesler B. et al . Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.  Gastroenterology . 2002;  123 1070-1083
    CrossrefPubMedGoogle Scholar
  • 24 Herrmann E, Neumann A U, Schmidt J M, Zeuzem S. Hepatitis C virus kinetics.  Antivir Ther . 2000;  5 85-90
    PubMedGoogle Scholar
  • 25 Zeuzem S, Herrmann E, Lee J H. et al . Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.  Gastroenterology . 2001;  120 1438-1447
    PubMedGoogle Scholar
  • 26 Wang Y-S, Youngster S, Grace M. et al . Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.  Advanced Drug Delivery Reviews . 2002;  54 547-570
    CrossrefPubMedGoogle Scholar
  • 27 Buti M, Sanchez-Avila F, Lurie Y. et al . Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.  Hepatology . 2002;  35 930-936
    CrossrefPubMedGoogle Scholar
  • 28 Bruno R, Debiaggi M, Ciappina V. et al . Hepatitis C virus dynamics during therapy with peginterferon alfa-2a compared with peginterferon alfa-2b in naive patients with chronic hepatitis C (Abst).  Hepatology . 2002;  36(Suppl) 206A
    PubMedGoogle Scholar
      >